(3E)-3-[(3,4-difluorophenyl)methylidene]-1-methyl-2-oxo-6-(3-phenylprop-1-ynyl)-2lambda4,1-benzothiazin-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: (3E)-3-[(3,4-difluorophenyl)methylidene]-1-methyl-2-oxo-6-(3-phenylprop-1-ynyl)-2lambda4,1-benzothiazin-4-one
• 英文别名: (3E)-3-[(3,4-difluorophenyl)methylidene]-1-methyl-2-oxo-6-(3-phenylprop-1-ynyl)-2λ4,1-benzothiazin-4-one
• 化学式: C₂₅H₁₇F₂NO₂S
• 分子量: 433.5
• InChiKey: ZBQQEVXPVJOYKX-LFVJCYFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  56.6
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] DERIVES D'HETEROARYLES FUSIONNES EN 6,6 UTILISES COMME INHIBITEURS DE METALLOPROTEASES MATRICIELLES
  申请人：WARNER LAMBERT CO

  公开号：WO2004014388A1

  公开（公告）日：2004-02-19

  This invention provides compounds defined by Formula (I) or a pharmaceutically acceptable salt thereof, wherein R?l, Q, Yl, Y2, Y3Y, R2a, R2b, R5¿, and n are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula (I) and the use of the compounds of Formula (I) as matrix metalloproteinase inhibitors.

  本发明提供了公式（I）或其药学上可接受的盐所定义的化合物，其中R?l，Q，Yl，Y2，Y3Y，R2a，R2b，R5¿和n如规范中所定义。本发明还提供了包含公式（I）化合物的制药组合物，并且提供了将公式（I）化合物用作基质金属蛋白酶抑制剂的用途。
• 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20040043985A1

  公开（公告）日：2004-03-04

  This invention provides compounds defined by Formula I 1 or a pharmaceutically acceptable salt thereof, wherein R 1 , Q, Y 1 , Y 2 , Y 3 , R 2a , R 2b , R 5 , and n are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods of treating diseases such as heart disease, multiple sclerosis, osteo- and rheumatoid arthritis, arthritis other than osteo- or rheumatoid arthritis, cardiac insufficiency, inflammatory bowel disease, heart failure, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, atherosclerosis, and osteoporosis in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component as described in the specification.

  本发明提供了由公式I1定义的化合物或其药学上可接受的盐，其中R1、Q、Y1、Y2、Y3、R2a、R2b、R5和n如规范中所定义。本发明还提供了药学组合物，包括由规范中定义的公式I的化合物或其药学上可接受的盐以及药学上可接受的载体、稀释剂或赋形剂。本发明还提供了在动物体内抑制MMP-13酶的方法，包括向动物体内给予公式I的化合物或其药学上可接受的盐。本发明还提供了治疗由MMP-13酶介导的疾病的方法，包括向患者内给予公式I的化合物或其药学上可接受的盐，单独或在药学组合物中。本发明还提供了治疗心脏病、多发性硬化症、骨关节炎和类风湿性关节炎、除骨关节炎或类风湿性关节炎之外的关节炎、心力衰竭、炎性肠病、年龄相关性黄斑变性、慢性阻塞性肺病、哮喘、牙周疾病、银屑病、动脉粥样硬化和骨质疏松症的方法，包括向患者内给予公式I的化合物或其药学上可接受的盐，单独或在药学组合物中。本发明还提供了组合物，包括公式I的化合物或其药学上可接受的盐，以及规范中描述的另一种药学活性成分。